CA3246860A1 - TRANSCRIPTOME ANALYSIS FOR THE TREATMENT OF INFLAMMATION - Google Patents

TRANSCRIPTOME ANALYSIS FOR THE TREATMENT OF INFLAMMATION

Info

Publication number
CA3246860A1
CA3246860A1 CA3246860A CA3246860A CA3246860A1 CA 3246860 A1 CA3246860 A1 CA 3246860A1 CA 3246860 A CA3246860 A CA 3246860A CA 3246860 A CA3246860 A CA 3246860A CA 3246860 A1 CA3246860 A1 CA 3246860A1
Authority
CA
Canada
Prior art keywords
dupilumab
treatment
genes
gene expression
gene
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3246860A
Other languages
English (en)
French (fr)
Inventor
Wei Keat Lim
Kaitlyn Gayvert
Sivan Harel
Jennifer Davidson HAMILTON
Sara Hamon
Matthew F. WIPPERMAN
Original Assignee
Regeneron Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Regeneron Pharmaceuticals Inc filed Critical Regeneron Pharmaceuticals Inc
Publication of CA3246860A1 publication Critical patent/CA3246860A1/en
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6809—Methods for determination or identification of nucleic acids involving differential detection
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6869—Methods for sequencing
    • C12Q1/6874—Methods for sequencing involving nucleic acid arrays, e.g. sequencing by hybridisation
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2539/00—Reactions characterised by analysis of gene expression or genome comparison
    • C12Q2539/10—The purpose being sequence identification by analysis of gene expression or genome comparison characterised by
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/112—Disease subtyping, staging or classification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/118—Prognosis of disease development
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Analytical Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • General Engineering & Computer Science (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Pathology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
CA3246860A 2022-04-26 2023-04-25 TRANSCRIPTOME ANALYSIS FOR THE TREATMENT OF INFLAMMATION Pending CA3246860A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202263334837P 2022-04-26 2022-04-26
US63/334,837 2022-04-26
PCT/US2023/066197 WO2023212569A1 (en) 2022-04-26 2023-04-25 Transcriptome analysis for treating inflammation

Publications (1)

Publication Number Publication Date
CA3246860A1 true CA3246860A1 (en) 2023-11-02

Family

ID=86469406

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3246860A Pending CA3246860A1 (en) 2022-04-26 2023-04-25 TRANSCRIPTOME ANALYSIS FOR THE TREATMENT OF INFLAMMATION

Country Status (8)

Country Link
US (1) US20230340601A1 (https=)
EP (1) EP4514995A1 (https=)
JP (1) JP2025515307A (https=)
CN (1) CN119137282A (https=)
AU (1) AU2023259352A1 (https=)
CA (1) CA3246860A1 (https=)
MX (1) MX2024013120A (https=)
WO (1) WO2023212569A1 (https=)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN117949666B (zh) * 2024-01-12 2025-07-15 首都医科大学附属北京同仁医院 一种预测或评估抗IL-4Rα单抗在治疗鼻黏膜2型炎症相关鼻病疗效的标志物、方法和应用
WO2025244092A1 (ja) * 2024-05-23 2025-11-27 国立研究開発法人理化学研究所 アトピー性皮膚炎患者へのデュピルマブの投与の有効性を予測する方法及びキット
WO2025244094A1 (ja) * 2024-05-23 2025-11-27 国立研究開発法人理化学研究所 アトピー性皮膚炎患者へのデュピルマブの投与の有効性を予測する方法及びキット
CN119932179B (zh) * 2025-04-08 2025-06-27 杭州易文赛生物技术有限公司 用于评价间充质干细胞治疗炎症性肠炎效果的标志物组合物及其应用
CN120510912A (zh) * 2025-05-20 2025-08-19 北京大学人民医院 用于溃疡性结肠炎预测计算机装置及计算机可读存储介质
CN121109581B (zh) * 2025-11-17 2026-03-06 杭州易文赛生物技术有限公司 用于评价间充质干细胞治疗特应性皮炎效果的标志物组合物及其应用

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR098155A1 (es) * 2013-10-23 2016-05-04 Genentech Inc Métodos para diagnosticar y tratar trastornos eosinofílicos
WO2019217478A1 (en) * 2018-05-09 2019-11-14 Dermtech, Inc. Novel gene classifiers and uses thereof in autoimmune diseases
EP4153300A1 (en) * 2020-05-22 2023-03-29 Regeneron Pharmaceuticals, Inc. Methods for treating eosinophilic esophagitis by administering an il-4r inhibitor

Also Published As

Publication number Publication date
US20230340601A1 (en) 2023-10-26
WO2023212569A1 (en) 2023-11-02
EP4514995A1 (en) 2025-03-05
MX2024013120A (es) 2024-12-06
AU2023259352A1 (en) 2024-10-10
CN119137282A (zh) 2024-12-13
JP2025515307A (ja) 2025-05-14

Similar Documents

Publication Publication Date Title
US12105089B2 (en) Cell atlas of the healthy and ulcerative colitis human colon
US12421557B2 (en) Methods for predicting outcomes and treating colorectal cancer using a cell atlas
US20230340601A1 (en) Transcriptome Analysis For Treating Inflammation
US10166210B2 (en) Methods of subtyping CRC and their association with treatment of colon cancer patients with oxaliplatin
EP2925885B1 (en) Molecular diagnostic test for cancer
US20210139987A1 (en) Methods, computer-readable media, and systems for assessing samples and wounds, predicting whether a wound will heal, and monitoring effectiveness of a treatment
US20150315643A1 (en) Blood transcriptional signatures of active pulmonary tuberculosis and sarcoidosis
US20240282449A1 (en) Methods and systems for machine learning analysis of inflammatory skin diseases
US20220162705A1 (en) Method for predicting the response to cancer immunotherapy in cancer patients
US20220399116A1 (en) Systems and methods for assessing a bacterial or viral status of a sample
US20240219385A1 (en) Molecular signatures of long-term covid-19 and treatment thereof
US20190367964A1 (en) Dissociation of human tumor to single cell suspension followed by biological analysis
US20250011886A1 (en) Systems and Methods for Targeting COVID-19 Therapies
US20250391505A1 (en) Methods and Systems for Machine Learning Analysis of Lupus Nephritis
US11815509B2 (en) Cell line and uses thereof
US20260110034A1 (en) Improved methods to diagnose head and neck cancer and uses thereof
US20240254565A1 (en) Unique cancer associated fibroblast subsets predict response to immunotherapy
US20240150453A1 (en) Methods of predicting response to anti-tnf blockade in inflammatory bowel disease
US20210071250A1 (en) Diagnostic and prognostic liquid biopsy biomarkers for asthma
US20260112450A1 (en) Methods for selection of cancer patients for anti-angiogenic and immune checkpoint blockage therapies and combinations thereof
Park et al. Gene expression profile in patients with axial spondyloarthritis: meta-analysis of publicly accessible microarray datasets
US20100112568A1 (en) Methods and kits for diagnosis of multiple sclerosis in probable multiple sclerosis subjects
EP4676593A1 (en) Diagnosing and treating atopic dermatitis, psoriasis, and/or mycosis fungoides
US20240132976A1 (en) Methods of stratifying and treating coronavirus infection
US20260117297A1 (en) Longitudinal Gene Expression Analysis of Inflammatory Skin Diseases

Legal Events

Date Code Title Description
A00 Application filed

Free format text: ST27 STATUS EVENT CODE: A-0-1-A10-A00-A101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION RECEIVED - PCT

Effective date: 20240925

A00 Application filed

Free format text: ST27 STATUS EVENT CODE: A-1-1-A10-A00-A102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: COMPLIANCE REQUIREMENTS DETERMINED MET

Effective date: 20241008

A15 Pct application entered into the national or regional phase

Free format text: ST27 STATUS EVENT CODE: A-1-1-A10-A15-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: NATIONAL ENTRY REQUIREMENTS DETERMINED COMPLIANT

Effective date: 20241008

P18 Priority claim added or amended

Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P18-P105 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: PRIORITY CLAIM REQUIREMENTS DETERMINED COMPLIANT

Effective date: 20241008

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20250213

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 2ND ANNIV.) - STANDARD

Year of fee payment: 2

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20250324

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20250808